2017
Wnt signaling, a novel pathway regulating blood pressure? State of the art review
Ziki M, Mani A. Wnt signaling, a novel pathway regulating blood pressure? State of the art review. Atherosclerosis 2017, 262: 171-178. PMID: 28522145, PMCID: PMC5508596, DOI: 10.1016/j.atherosclerosis.2017.05.001.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntihypertensive AgentsBlood PressureHumansHypertensionMolecular Targeted TherapyWnt ProteinsWnt Signaling PathwayConceptsBP regulationType 2 diabetes mellitusBlood pressure targetsPathogenesis of hypertensionTight BP controlTherapy of hypertensionField of hypertensionReview of PubMedDrug developmentNovel drug developmentAntihypertensive TrialBP controlDifferent metabolic profilesUnique molecular pathwaysPressure targetsBlood pressureDiabetes mellitusMetabolic syndromePatient populationHypertensionStudy populationHeterogeneous diseaseReference listsPrecision Medicine InitiativeContribution of Wnt
2015
New targets to treat obesity and the metabolic syndrome
Martin KA, Mani MV, Mani A. New targets to treat obesity and the metabolic syndrome. European Journal Of Pharmacology 2015, 763: 64-74. PMID: 26001373, PMCID: PMC4573317, DOI: 10.1016/j.ejphar.2015.03.093.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCardiovascular DiseasesHumansMetabolic SyndromeMolecular Targeted TherapyObesityRisk FactorsConceptsMetabolic syndromeCardiovascular diseaseGlucagon-like peptide-1 receptor agonistsPancreatic lipase inhibitor orlistatSingle CVD risk factorPeptide-1 receptor agonistsCVD risk factorsEpidemic of obesityLong-term treatmentType 2 diabetesLipase inhibitor orlistatDipeptidyl peptidase IV inhibitorsAnti-diabetic drugsFuture drug developmentTruncal obesitySerotonergic drugsReceptor agonistRisk factorsMelanocortin systemObesityMetabolic traitsSyndromeMetabolic profileIV inhibitorsNew targets